

Category of Adverse Events, by patient and overall

	Treatment group			Overall	
	HLSCs 125,000 cells/ gram of liver	HLSCs 250,000 cells/ gram of liver			
	pz 01-001	pz 01-002	pz 01-003	events n (%)	subjects n (%)
Total AEs	6	2	4	12	3 (100 %)
SOC <i>PPT MedDRA</i>					
Blood and lymphatic system disorders	1	0	0	1 (8.3%)	1 (33.3%)
<i>Thrombocytosis</i>	<i>1</i>			<i>1</i>	<i>1</i>
Epidermal and dermal conditions	1	1	0	2 (16.7%)	2 (66.7%)
<i>Dermatitis</i>	<i>1</i>	<i>1</i>		<i>2</i>	<i>2</i>
Eye disorder	1	0	0	1 (8.3%)	1 (33.3%)
<i>Eyelid edema</i>	<i>1</i>			<i>1</i>	<i>1</i>
Gastrointestinal disorders	1	0	0	1 (8.3%)	1 (33.3%)
<i>Diarrhea</i>	<i>1</i>			<i>1</i>	<i>1</i>
Gastrointestinal signs and symptoms	0	0	1	1 (8.3%)	1 (33.3%)
<i>Vomiting</i>			<i>1</i>	<i>1</i>	<i>1</i>
Nervous system disorders	1	0	1	2 (16.7%)	2 (66.7%)
<i>Agitation neonatal</i>	<i>1</i>			<i>1</i>	<i>1</i>
<i>Tremor</i>			<i>1</i>	<i>1</i>	<i>1</i>
Renal and urinary disorders	1	1	1	3 (25%)	3 (100%)
<i>Urinary abnormalities Leukocyturia</i>	<i>1</i>			<i>1</i>	<i>1</i>
<i>Urinary tract infection</i>		<i>1</i>	<i>1</i>	<i>2</i>	<i>2</i>
Skin and subcutaneous tissue disorders	0	0	1	1 (8.3%)	1 (33.3%)
<i>Skin rash</i>			<i>1</i>	<i>1</i>	<i>1</i>